QingSong Health Corporation (HKEX: 02661) has completed the integration of its self-developed AI evidence-based medical agent, “QSevidence,” into the Group’s professional healthcare platform, QSmedical. The move combines proprietary AI capabilities with a large-scale physician service network to provide interpretable, verifiable and traceable decision support in real-world clinical settings.

According to internal data, QSmedical recorded 69,615 medical professional users as of 31 March 2026, up 46.40% from 47,554 a year earlier. Within this total:

• Ophthalmology specialists grew to 3,672, an increase of 171.00% compared with 1,355 the previous year. • Physicians at or above associate chief physician level reached 36,678, representing 52.70% of total users and a 42.70% year-on-year rise from 25,701.

Management highlighted that more than half of platform users now hold senior medical titles, underscoring the professional depth of digital services offered.

QingSong Health has articulated a three-layer AI roadmap built on its AIcare technology stack:

1. i-DataCloud – foundational AI infrastructure for all business lines. 2. Dr.GPT – a vertical medical large language model underpinning healthcare intelligence. 3. QSevidence agents – evidence-based applications aimed at supporting physicians in complex clinical scenarios.

The company plans to expand AI agent deployment across evidence-based medicine, clinical decision-making, physician services and public health management, seeking to establish a comprehensive AI service matrix for both professionals and end users.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.